InterCure Ltd
InterCure Ltd is a biopharmaceutical company operating in the Health Care sector, specifically within Pharmaceuticals, though its specific activity remains unclassified in the provided data.
Business. InterCure Ltd is a biopharmaceutical company operating in the Health Care sector, specifically within Pharmaceuticals, though its specific activity remains unclassified in the provided data.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
InterCure Ltd is a biopharmaceutical company operating in the Health Care sector, specifically within Pharmaceuticals, though its specific activity remains unclassified in the provided data.
InterCure Ltd maintains a capital structure characterized by significant leverage relative to its equity base, with long-term debt of ILS 183.0 million against total equity of ILS 396.5 million, resulting in a debt-to-equity ratio of 0.46. The company holds ILS 46.5 million in cash and equivalents, which is insufficient to cover its total liabilities of ILS 294.0 million, leading to a negative net cash position. Liquidity is assessed as medium risk, supported by a current ratio of 1.48, indicating short-term assets exceed short-term liabilities but with limited buffer. The market capitalization stands at ILS 17.6 billion, implying a high valuation multiple relative to its book value, with a price-to-book ratio of 44.3.
Profitability metrics indicate the company is currently unprofitable, reporting a net income loss of ILS 35.7 million and an operating income loss of ILS 27.2 million. Return on equity is negative at -9.01%, and return on assets is negative at -5.17%, reflecting the inability to generate returns on its asset base of ILS 690.6 million. The enterprise value to EBITDA ratio is negative at -649.82, and the EV-to-revenue ratio is 65.52, suggesting the market is pricing in significant future growth potential or asset value not reflected in current earnings. Gross profit is positive at ILS 40.7 million, indicating that core operations generate some margin before operating expenses, but this is insufficient to cover overhead and interest costs.
Segment and geographic revenue data are not provided in the input, preventing an analysis of revenue concentration or regional exposure. The company's revenue of ILS 270.2 million is treated as a consolidated figure without breakdown by product line or geography.
Historical period data for revenue and net income trends are absent, limiting the ability to assess growth trajectory or consistency of performance over time. The current financial snapshot represents the latest normalized period, but without historical context, the direction of revenue growth or margin expansion cannot be determined from the provided data.
Risk assessment highlights medium liquidity risk and low dilution risk. A key flag is the negative net cash position after subtracting total debt, which increases financial vulnerability to interest rate changes or refinancing difficulties. The low dilution risk suggests that the company is not currently issuing significant new shares, as basic and diluted shares outstanding are identical at 59.2 million.
Recent filing, news, and transcript observations are not provided in the input data. Therefore, no specific recent events, management signals, or competitor context can be integrated into the narrative. The analysis relies solely on the static financial and classification data provided.
- High valuation multiples (P/B 44.3, EV/Rev 65.5) suggest market expectations for significant future growth despite current unprofitability.
- Negative net cash position and medium liquidity risk require monitoring of debt maturity profiles and cash burn rates.
- Low dilution risk is indicated by identical basic and diluted share counts, preserving current shareholder value from issuance.
- Negative ROE (-9.01%) and ROA (-5.17%) highlight the current inability to generate returns on invested capital.
- Lack of segment and historical data limits the depth of operational and trend analysis.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Reference data
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Ev To Revenueenterprise_value / revenue
- Market Capmarket_price * shares_outstanding_diluted
- Return On Assetsnet_income / total_assets
- Price To Tangible Bookmarket_price / (tangible_book_value / shares_outstanding_diluted)
- Enterprise Valuemarket_cap - net_cash
- InterCure Ltd Market data — financials · 2026-07-09
Ownership & reference
Top holders
- Investment Managers · as of 2024-06-300,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$0M